On the phenotype level, the expression of HER2 on DTCs or CTCs of patients with primary breast cancer has been published by different groups – who independently indicated that HER2 expression on both DTCs and CTCs differed from HER2 expression in the primary tumor and that the expression of HER2 on DTCs and CTCs was correlated with poor prognosis [32,43-46]. This evidence concerns the gene ERBB2 and neoplasm.